Dynacirc and Ear neoplasm malignant - a phase IV clinical study of FDA data
Summary:
We study 1,283 people who take Dynacirc (isradipine) or have Ear neoplasm malignant. No report of Ear neoplasm malignant is found in people who take Dynacirc.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Dynacirc?
Dynacirc has active ingredients of isradipine. eHealthMe is studying from 975 Dynacirc users. Check the latest studies of Dynacirc.
What is Ear Neoplasm Malignant?
Ear neoplasm malignant (ear cancerous tumour) is found to be associated with 52 drugs and 172 conditions by eHealthMe. Check the latest studies of Ear neoplasm malignant.
No report is found.
Do you take Dynacirc and have Ear neoplasm malignant?
- Check whether Ear neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Dynacirc:
- Dynacirc (975 reports)
Ear neoplasm malignant treatments and more:
- Ear neoplasm malignant (308 reports)
How severe was Ear neoplasm malignant and when was it recovered:
Expand to all the drugs that have ingredients of isradipine:
Browse all side effects of Dynacirc:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Ear neoplasm malignant:
Browse all the conditions that are associated with Ear neoplasm malignant:
How the study uses the data?
The study uses data from the FDA. It is based on isradipine (the active ingredients of Dynacirc) and Dynacirc (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Bactroban and Gastrointestinal Disorder for Men aged 20-29 - 4 seconds ago
- Could Atorvastatin Calcium cause Reading Disorder? - 4 seconds ago
- Could Lantus cause Erythema Multiforme? - 20 seconds ago
- Could Relafen cause Femoral Arterial Stenosis? - 20 seconds ago
- Hair Loss and Joint Pain - 29 seconds ago
- Sertraline and Speech Impairment (Adult) for Men aged 50-59 - 35 seconds ago
- Sertraline and Slurred Speech for Men aged 50-59 - 35 seconds ago
- Could Micardis cause Abortion? - 35 seconds ago
- Sertraline and Language Impairment for Men aged 50-59 - 36 seconds ago
- Sertraline and Inability To Speak for Men aged 50-59 - 36 seconds ago